Table 3.

Regression parameter and degree of significance from the Wald test of dose and squared dose on long term rate of change of PSA adjusted for iPSA, T-stage and Gleason as well as dose and squared dose on post-treatment PSA and short term drop of PSA, and derived estimate of the α/β ratio with 95% confidence bands for subgroups of prognostic factors.

Prognostic factor	Strate	Number of subjects (%)	Dose	Squared dose	α/β	95% CI *
T-stage	<2	1498 (29.4%)	-0.00854 (p=0.004)	-0.00342 (p=0.011)	2.55	[0.53;17.95]
	=2	3132 (61.5%)	-0.00422 (p=0.086)	-0.00449 (p=0.005)	0.94	[-0.20;5.67]
	>2	463 (9.1%)	-0.0210 (p=0.196)	-0.0150 (p=0.226)	1.98	]-∞;∞[
Gleason	<7	3567 (70.0%)	-0.0103 (p<0.001)	-0.0040 (p<0.001)	2.63	[1.29;6.67]
	=7	1177 (23.1%)	0.0071 (p=0.261)	-0.0079 (p=0.020)	-1.22	[-6.85;1.77]
	>7	349 (6.9%)	0.0234 (p=0.1772)	0.00123 (p=0.887)	14.71	]-∞;∞[
iPSA	≤10ng/mL	2775 (54.5%)	-0.0074 (p<0.001)	-0.00257 (p=0.013)	2.98	[0.94;23.12]
	>10ng/mL	2318 (45.5%)	-0.00245 (p=0.547)	-0.0688 (p=0.006)	0.29	[-0.97;3.38]

^*∞ was noted for bounds >1,000 or <1,000.